Manufacturers have adopted novel delivery platforms to drive global market growth.
Positive clinical trial results combined with assured safety profiles to meet the disease's unmet need are the major factors expected to boost the Hereditary Angioedema Market in the near future. For example, Arrowhead Pharmaceuticals' RNAi-based candidate ARC-F12 is currently in preclinical development as a potential treatment for factor XII (F12) mediated diseases. Because the RNAi-based candidate is expected to provide opportunities in the treatment of hereditary angioedema, Arrowhead is currently conducting research to advance the candidate into clinical trials.
Read More @ https://cmiinfonest.blogspot.com/2022/05/the-hereditary-angioedema-market-trends.html
